A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

Santen

Status and phase: Enrolling; Phase 3

Conditions: Open Angle Glaucoma; Ocular Hypertension

Treatments: Drug: Latanoprost; Drug: DE-117B Eye Drops

Study type: Interventional

Funder types: Industry

Identifiers

NCT06666855

0117B02CN

Details and patient eligibility

About

This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.

Subjects diagnosed with POAG (Primary Open Angle Glaucoma) or OHT (Ocular Hypertension) who meet eligibility criteria will washout of their current IOP lowering medication(s), if any.

The study will investigate plasma pharmacokinetics of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension.

It will investigate the safety of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension.

There will be a bridging cohort and extension follow-up phase

Enrollment: 338 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with primary open angle glaucoma or ocular hypertension in both eyes.
• Corrected visual acuity ≥0.2 in both eyes.
• Anterior chamber angle grade ≥2 (Shaffer scale) in both eyes.
• Central corneal thickness ≥480 μm to ≤600 μm in both eyes.
• At completion of the washout phase, IOP ≥22 mmHg in at least one eye and ≤34 mmHg in both eyes at all measurement time points.

Exclusion criteria

• Consider visual field disorder at risk for progression during the study based on the current clinical examination result.
• Severe visual field disorder (e.g., mean deviation lower than -12 dB, as assessed by Humphrey field analyzer).
• Any corneal abnormality or other condition potentially interfering with reliable applanation tonometry.
• History of iritis or uveitis.
• Presence of any active external ocular disease, inflammation, or infection of the eye or eyelids.
• History of macular oedema, retinal detachment, or diabetic retinopathy, or current retinal disease at risk for progression during the study.
• History of refractive keratotomy.
• History of invasive surgery for glaucoma (including laser therapy).
• Anterior segment or intraocular surgery (other than glaucoma) within 90 days prior to start of washout phase.
• History of severe eye injury.
• History of allergy to agents that were to be used during the study (e.g., benzalkonium chloride, instillation anesthetics, fluorescein, latanoprost eye drops).
• Intended use of prohibited concomitant medications or therapies during the study.
• Required use of contact lenses from 1 week before treatment phase initiation and during the study.
• Pseudophakic eye, aphakic eye.
• Current participation in another clinical study, or participation and treatment with study medication within 90 days before the start of the washout phase.
• Females who are pregnant, nursing, or potentially pregnant (e.g., positive pregnancy test), planning a pregnancy during the study, or unable to use appropriate contraception during the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

338 participants in 2 patient groups

DE-117B Eye Drops

Experimental group

Description:

0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for 4 weeks, followed by 0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for an extension follow-up phase of 12 months.

Treatment:

Drug: DE-117B Eye Drops

Latanoprost Eye Drops

Active Comparator group

Description:

0.005% Latanoprost Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for 4 weeks, followed by 0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for an extension follow-up phase of 12 months.

Treatment:

Drug: Latanoprost